Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Soligenix Inc. Stories

2013-12-02 08:30:44

Clinical Trial Supported by $300,000 NCI Grant PRINCETON, N.J., Dec. 2, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating...

2013-11-21 08:27:05

PRINCETON, N.J., Nov. 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC) providing an initial investment in Soligenix of $600,000 and...

2013-11-12 08:34:31

PRINCETON, N.J., Nov. 12, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the quarter and nine months ended September 30, 2013. Soligenix's revenues for the quarter and nine months ended were $0.3...

2013-10-31 08:32:49

PRINCETON, N.J., Oct. 31, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today submission of a full contract proposal to the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases. Successful...

2013-10-28 08:28:31

November 1, 2013 at 2:00 PM EDT PRINCETON, N.J., Oct. 28, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, Oreola Donini, PhD, Vice President of Preclinical Research and Development,...

2013-10-21 08:28:41

PRINCETON, N.J., Oct. 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today the appointment of Marco Maria Brughera, DVM, Global Head of the Rare Disease Franchise for Sigma-Tau SpA, to its Board of Directors. "We are pleased to welcome Dr. Brughera to...

2013-10-17 08:29:01

PRINCETON, N.J., Oct. 17, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today the formation of an international melioidosis Scientific Advisory Board (SAB). Comprised of clinicians and researchers from Australia, Thailand, Lao and The Netherlands with...

2013-10-03 08:29:41

PRINCETON, N.J., Oct. 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has appointed Oreola Donini, PhD, as its Vice President of Preclinical Research and Development. Dr. Donini has more than 13 years experience in drug discovery and...

2013-09-25 08:29:06

PRINCETON, N.J., Sept. 25, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded...

2013-09-19 08:28:24

PRINCETON, N.J., Sept. 19, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $26.3 million by the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority...